Riskpilot← Back to searchSign inGet full accessLAB PHARMA AS
ASActiveOrg 997105028Olav Selvaags Plass 4, 0252 OsloRetail sale of other food · NACE 4727Est. 20113 employeeswww.labpharma.no
Revenue 2024
NOK 26,2M
-13% vs 2023
EBITDA margin
-11.1%
-457% vs 2023
Equity ratio
-39.4%
Financial strength
Net profit 2024
NOK -3,9M
-335% vs 2023
| Revenue | NOK 26,2M | -13% |
| EBITDA | NOK -2,9M | -457% |
| Net profit | NOK -3,9M | -335% |
| Total assets | NOK 5,6M | -38% |
| Equity | NOK -2,2M | -232% |
| Employees | 3 | — |
Legal name
LAB PHARMA AS
Org number
997105028
Legal form
Aksjeselskap
NACE code
4727 · Retail sale of other food
Founded
4. juli 2011
Share capital
NOK 500 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og nestleder hver for seg. Styrets medlemmer hver for seg.
Company purpose
Utvikling og salg av helsekostprodukter og naturlegemidler, samt alt som hører naturlig til dette, herunder å delta i andre selskaper.
Address
Olav Selvaags Plass 4, 0252 Oslo
Website
www.labpharma.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 78 | 3 027 | 11 102 | 9 672 | 19 117 | 25 883 | 43 479 | 56 159 | 47 182 | 33 604 | 22 600 | 22 365 | 30 157 | 26 222 |
| Staff expenses | −0 | −221 | −2 288 | −1 975 | −1 622 | −3 553 | −2 315 | −3 103 | −3 951 | −3 492 | −3 343 | −3 354 | −3 433 | −3 471 |
| EBITDA | −147 | −318 | 1 436 | −2 321 | 7 557 | 7 620 | 11 105 | 9 844 | 4 907 | −1 271 | −1 320 | −1 818 | 815 | −2 908 |
| Depreciation & amort. | −12 | −46 | −70 | −71 | −35 | −42 | −43 | −34 | −35 | −32 | −29 | −40 | −40 | −28 |
| EBIT | −159 | −363 | 1 365 | −2 392 | 7 522 | 7 577 | 11 062 | 9 811 | 4 872 | −1 304 | −1 349 | −1 857 | 775 | −2 936 |
| Net financials | −10 | −73 | −301 | −53 | −46 | 92 | 416 | 65 | −442 | 1 440 | 203 | 1 010 | 1 343 | 302 |
| Profit before tax | −169 | −436 | 1 064 | −2 446 | 7 476 | 7 669 | 11 478 | 9 876 | 4 429 | 136 | −1 146 | −847 | 2 118 | −2 634 |
| Tax | −0 | −0 | 255 | −0 | 1 289 | 1 941 | 2 825 | 2 390 | 977 | 30 | −252 | −186 | 466 | 1 247 |
| Net profit | −169 | −436 | 810 | −2 446 | 6 186 | 5 728 | 8 653 | 7 486 | 3 452 | 106 | −894 | −661 | 1 652 | −3 881 |
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 403 | 2 065 | 3 574 | 1 505 | 7 477 | 6 314 | 12 781 | 12 753 | 8 307 | 5 851 | 4 713 | 4 765 | 8 971 | 5 605 |
| Equity | −69 | −106 | 704 | −1 742 | 500 | 2 228 | 3 882 | 1 214 | 2 667 | 1 573 | 679 | 18 | 1 670 | −2 211 |
| Long-term debt | 475 | 1 966 | 358 | 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | −3 | 205 | 2 512 | 2 987 | 6 977 | 4 086 | 8 899 | 11 538 | 5 641 | 4 278 | 4 034 | 4 747 | 7 301 | 7 815 |
| Total debt | 472 | 2 171 | 2 870 | 3 247 | 6 977 | 4 086 | 8 899 | 11 538 | 5 641 | 4 278 | 4 034 | 4 747 | 7 301 | 7 815 |
EBITDA margin
-11.1%
This company
15.8%
Market median
-170% vs market
20112024
Equity ratio
-39.4%
This company
38.2%
Market median
-203% vs market
20112024
Return on equity
-388109500.0%
This company
18.4%
Market median
-2109290861% vs market
20112024
Net profit margin
-14.8%
This company
8.1%
Market median
-283% vs market
20112024
Asset turnover
4.68×
This company
1.12×
Market median
+318% vs market
20112024
Debt / equity
3.54×
This company
0.62×
Market median
-471% vs market
20112024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-06-16 – 2011-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2016 | — | — | |
| Chairman | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Ter Rek As | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ter Rek As
LAB PHARMA AS Board members of LAB PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Cybele Hoftun | Board of Directors | 0 companies |
| Haakon Ringerike Hoftun | Chairman | 0 companies |